The effects gradually taper off as more of the medication is eliminated, with most people starting to experience food cravings and hunger a week after their last injection
Medicare beneficiaries who are already receiving coverage from their Part D plan for a GLP-1 for a Medicare-covered use, such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, will continue to access the drug through their Part D plan and not through the Medicare GLP-1 Bridge, which will only provide coverage of GLP-1s when used for obesity
Background The relative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for kidney protection, both individually and in combination, is incompletely understood
It does not mean the medication is toxic or dangerous. However, you should always discuss any side effects with your medical provider to ensure your dosage is appropriate
Considering Your Comfort Choosing the right b12 injection site involves assessing your comfort level and ensuring the sites accessibility